Compile Data Set for Download or QSAR
Report error Found 1997 for UniProtKB: P12497
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM407(N-[5-tert-butyl-4-({4-hydroxy-6-[2-(4-hydroxypheny...)
Affinity DatapH: 6.2 T: 2°CAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM415(N-(4-{[5-tert-butyl-4-({4-hydroxy-6-[2-(4-hydroxyp...)
Affinity DatapH: 6.2 T: 2°CAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM704((4R)-N-tert-butyl-3-[(2S,3S)-2-hydroxy-3-(2-phenox...)
Affinity DatapH: 6.0 T: 2°CAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Substrates and cleavage fragments...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM705((R)-N-tert-Butyl-3-[(2S,3S)-2-hydroxy-3-(2-methylp...)
Affinity DatapH: 6.0 T: 2°CAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Substrates and cleavage fragments...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM706((R)-N-tert-Butyl-3-[(2S,3S)-2-hydroxy-3-(3-methylp...)
Affinity DatapH: 6.0 T: 2°CAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Substrates and cleavage fragments...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM707((R)-N-tert-Butyl-3-[(2S,3S)-2-hydroxy-3-(4-methylp...)
Affinity DatapH: 6.0 T: 2°CAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Substrates and cleavage fragments...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM709((4R)-N-tert-butyl-3-[(2S,3S)-3-[2-(2-ethyl-6-methy...)
Affinity DatapH: 6.0 T: 2°CAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Substrates and cleavage fragments...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM710((R)-N-tert-Butyl-3-[(2S,3S)-2-hydroxy-3-(2-methyl-...)
Affinity DatapH: 6.0 T: 2°CAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Substrates and cleavage fragments...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM711((R)-N-tert-Butyl-3-[(2S,3S)-3-(2,6-diethylpropylph...)
Affinity DatapH: 6.0 T: 2°CAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Substrates and cleavage fragments...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM781(4-hydroxy-3-(1-phenylethyl)-2H,5H,6H,7H,8H,9H,10H-...)
Affinity DatapH: 5.0 T: 2°CAssay Description:HIV-1 protease was purified and refolded from E. coli inclusion bodies. The substrate used spans the p17-p24 processing site (R-V-S-Q-N-Y-P-I-V-Q-N-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/16/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM790(3-benzyl-4-hydroxy-2H,5H,6H,7H,8H,9H,10H-cycloocta...)
Affinity DatapH: 5.0 T: 2°CAssay Description:HIV-1 protease was purified and refolded from E. coli inclusion bodies. The substrate used spans the p17-p24 processing site (R-V-S-Q-N-Y-P-I-V-Q-N-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/16/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM791(4-hydroxy-3-(2-phenylethyl)-2H,5H,6H,7H,8H,9H,10H-...)
Affinity DatapH: 5.0 T: 2°CAssay Description:HIV-1 protease was purified and refolded from E. coli inclusion bodies. The substrate used spans the p17-p24 processing site (R-V-S-Q-N-Y-P-I-V-Q-N-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/16/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM792(4-hydroxy-3-(3-phenylpropyl)-2H,5H,6H,7H,8H,9H,10H...)
Affinity DatapH: 5.0 T: 2°CAssay Description:HIV-1 protease was purified and refolded from E. coli inclusion bodies. The substrate used spans the p17-p24 processing site (R-V-S-Q-N-Y-P-I-V-Q-N-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/16/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM794((2S)-N-[(2S,3S)-4-[4-(tert-butylcarbamoyl)-1,3-thi...)
Affinity DatapH: 6.2 T: 2°CAssay Description:Inhibition constants were determined by a fluorometric assay with the fluorogenic substrate Arg-Glu(EDANS)-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Lys(DABCYL)-Ar...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/17/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM897(methyl (2S)-2-{[(tert-butoxy)carbonyl]amino}-2-[(5...)
Affinity DatapH: 5.5 T: 2°CAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/8/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM898((2S)-2-benzyl-4-[(2S)-4-[(2R,3R,4S)-1-cyclohexyl-3...)
Affinity DatapH: 5.5 T: 2°CAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/8/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM899((2R)-2-[(5S)-5-benzyl-5-[2-(morpholin-4-yl)-2-oxoe...)
Affinity DatapH: 5.5 T: 2°CAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/8/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM1158((4S,5R,6R,7S)-1,3-dibenzyl-5,6-dihydroxy-4,7-bis(p...)
Affinity DatapH: 5.5 T: 2°CAssay Description:The IC50 value is the inhibitor concentration that results in 50% of HIV-1 protease activity measured by a spectrophotometric assay using a chromopho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM1159((4S,5S,6S,7S)-1,3-Dibenzyl-4,7-bis(phenoxymethyl)-...)
Affinity DatapH: 5.5 T: 2°CAssay Description:The IC50 value is the inhibitor concentration that results in 50% of HIV-1 protease activity measured by a spectrophotometric assay using a chromopho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM1160((4R,5R,6R,7R)-1,3-dibenzyl-5,6-dihydroxy-4,7-bis(p...)
Affinity DatapH: 5.5 T: 2°CAssay Description:The IC50 value is the inhibitor concentration that results in 50% of HIV-1 protease activity measured by a spectrophotometric assay using a chromopho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM2200(3-{[2-tert-butyl-4-(hydroxymethyl)-5-methylphenyl]...)
Affinity DataAssay Description:For determination of IC50 values, HIV-1 protease was added to assay buffer containing inhibitor and the substrate (H-His-Lys-Ala-Arg-Val-Leu- (p-NO2)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM2531(3-{[2-tert-butyl-4-(hydroxymethyl)-5-methylphenyl]...)
Affinity DatapH: 6.2 T: 2°CAssay Description:For determination of IC50 values, HIV-1 protease was added to assay buffer containing inhibitor and the substrate (H-His-Lys-Ala-Arg-Val-Leu- (p-NO2)...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/8/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM3402(2-[4-(tert-Butylcarbamoyl)phenyl]-2-hydroxybut-3-e...)
Affinity DatapH: 5.6 T: 2°CAssay Description:Protease activity was measured by continuous chromogenic assay. The chromogenic peptide His-Lys-Ala-Arg-Val-Leu- (p-NO2-Phe)-Glu-Ala-Nleu-Ser (Bache...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/25/2005
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM3404(N-tert-butyl-1-{4-[2-(tert-butylcarbamoyl)phenyl]-...)
Affinity DatapH: 5.6 T: 2°CAssay Description:Protease activity was measured by continuous chromogenic assay. The chromogenic peptide His-Lys-Ala-Arg-Val-Leu- (p-NO2-Phe)-Glu-Ala-Nleu-Ser (Bache...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/25/2005
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM3405((2S)-N-tert-butyl-1-[(2R)-4-[1-(tert-butylcarbamoy...)
Affinity DatapH: 5.6 T: 2°CAssay Description:Protease activity was measured by continuous chromogenic assay. The chromogenic peptide His-Lys-Ala-Arg-Val-Leu- (p-NO2-Phe)-Glu-Ala-Nleu-Ser (Bache...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/25/2005
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM3406((2S)-N-tert-butyl-1-[(2S)-4-[1-(tert-butylcarbamoy...)
Affinity DatapH: 5.6 T: 2°CAssay Description:Protease activity was measured by continuous chromogenic assay. The chromogenic peptide His-Lys-Ala-Arg-Val-Leu- (p-NO2-Phe)-Glu-Ala-Nleu-Ser (Bache...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/25/2005
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587,Q496K](Human immunodeficiency virus type 1)
Viiv Healthcare UK (NO.5)

US Patent
LigandPNGBDBM293264(US10106504, Example 1)
Affinity DataEC50: >1.00E+3nMpH: 7.55Assay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetGag-Pol polyprotein [489-587,Q496K](Human immunodeficiency virus type 1)
Viiv Healthcare UK (NO.5)

US Patent
LigandPNGBDBM293264(US10106504, Example 1)
Affinity DataEC50:  1.74E+3nMpH: 7.55Assay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetGag-Pol polyprotein [489-587,Q496K](Human immunodeficiency virus type 1)
Viiv Healthcare UK (NO.5)

US Patent
LigandPNGBDBM293265(US10106504, Example 2)
Affinity DataEC50: <100nMpH: 7.55Assay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetGag-Pol polyprotein [489-587,Q496K](Human immunodeficiency virus type 1)
Viiv Healthcare UK (NO.5)

US Patent
LigandPNGBDBM293265(US10106504, Example 2)
Affinity DataEC50:  73nMpH: 7.55Assay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetGag-Pol polyprotein [489-587,Q496K](Human immunodeficiency virus type 1)
Viiv Healthcare UK (NO.5)

US Patent
LigandPNGBDBM293266(US10106504, Example 3)
Affinity DataEC50:  550nMpH: 7.55Assay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetGag-Pol polyprotein [489-587,Q496K](Human immunodeficiency virus type 1)
Viiv Healthcare UK (NO.5)

US Patent
LigandPNGBDBM293266(US10106504, Example 3)
Affinity DataEC50:  196nMpH: 7.55Assay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetGag-Pol polyprotein [489-587,Q496K](Human immunodeficiency virus type 1)
Viiv Healthcare UK (NO.5)

US Patent
LigandPNGBDBM293267(US10106504, Example 4)
Affinity DataEC50:  550nMpH: 7.55Assay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetGag-Pol polyprotein [489-587,Q496K](Human immunodeficiency virus type 1)
Viiv Healthcare UK (NO.5)

US Patent
LigandPNGBDBM293268(US10106504, Example 5)
Affinity DataEC50:  550nMpH: 7.55Assay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetGag-Pol polyprotein [489-587,Q496K](Human immunodeficiency virus type 1)
Viiv Healthcare UK (NO.5)

US Patent
LigandPNGBDBM293269(US10106504, Example 6)
Affinity DataEC50: <100nMpH: 7.55Assay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetGag-Pol polyprotein [489-587,Q496K](Human immunodeficiency virus type 1)
Viiv Healthcare UK (NO.5)

US Patent
LigandPNGBDBM293270(US10106504, Example 7)
Affinity DataEC50:  550nMpH: 7.55Assay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetGag-Pol polyprotein [489-587,Q496K](Human immunodeficiency virus type 1)
Viiv Healthcare UK (NO.5)

US Patent
LigandPNGBDBM293270(US10106504, Example 7)
Affinity DataEC50:  545nMpH: 7.55Assay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetGag-Pol polyprotein [489-587,Q496K](Human immunodeficiency virus type 1)
Viiv Healthcare UK (NO.5)

US Patent
LigandPNGBDBM293271(US10106504, Example 8)
Affinity DataEC50:  550nMpH: 7.55Assay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetGag-Pol polyprotein [489-587,Q496K](Human immunodeficiency virus type 1)
Viiv Healthcare UK (NO.5)

US Patent
LigandPNGBDBM293272(US10106504, Example 9)
Affinity DataEC50: <100nMpH: 7.55Assay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetGag-Pol polyprotein [489-587,Q496K](Human immunodeficiency virus type 1)
Viiv Healthcare UK (NO.5)

US Patent
LigandPNGBDBM293273(US10106504, Example 10)
Affinity DataEC50: <100nMpH: 7.55Assay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetGag-Pol polyprotein [489-587,Q496K](Human immunodeficiency virus type 1)
Viiv Healthcare UK (NO.5)

US Patent
LigandPNGBDBM293274(US10106504, Example 11)
Affinity DataEC50: <100nMpH: 7.55Assay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetGag-Pol polyprotein [489-587,Q496K](Human immunodeficiency virus type 1)
Viiv Healthcare UK (NO.5)

US Patent
LigandPNGBDBM293275(US10106504, Example 12)
Affinity DataEC50: <100nMpH: 7.55Assay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetGag-Pol polyprotein [489-587,Q496K](Human immunodeficiency virus type 1)
Viiv Healthcare UK (NO.5)

US Patent
LigandPNGBDBM293275(US10106504, Example 12)
Affinity DataEC50:  7nMpH: 7.55Assay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetGag-Pol polyprotein [489-587,Q496K](Human immunodeficiency virus type 1)
Viiv Healthcare UK (NO.5)

US Patent
LigandPNGBDBM293276(US10106504, Example 13)
Affinity DataEC50: <100nMpH: 7.55Assay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetGag-Pol polyprotein [489-587,Q496K](Human immunodeficiency virus type 1)
Viiv Healthcare UK (NO.5)

US Patent
LigandPNGBDBM293277(US10106504, Example 14)
Affinity DataEC50: <100nMpH: 7.55Assay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetGag-Pol polyprotein [489-587,Q496K](Human immunodeficiency virus type 1)
Viiv Healthcare UK (NO.5)

US Patent
LigandPNGBDBM293278(US10106504, Example 15)
Affinity DataEC50: <100nMpH: 7.55Assay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetGag-Pol polyprotein [489-587,Q496K](Human immunodeficiency virus type 1)
Viiv Healthcare UK (NO.5)

US Patent
LigandPNGBDBM293279(US10106504, Example 16)
Affinity DataEC50: <100nMpH: 7.55Assay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetGag-Pol polyprotein [489-587,Q496K](Human immunodeficiency virus type 1)
Viiv Healthcare UK (NO.5)

US Patent
LigandPNGBDBM293280(US10106504, Example 17)
Affinity DataEC50: <100nMpH: 7.55Assay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetGag-Pol polyprotein [489-587,Q496K](Human immunodeficiency virus type 1)
Viiv Healthcare UK (NO.5)

US Patent
LigandPNGBDBM293281(US10106504, Example 18)
Affinity DataEC50: <100nMpH: 7.55Assay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

TargetGag-Pol polyprotein [489-587,Q496K](Human immunodeficiency virus type 1)
Viiv Healthcare UK (NO.5)

US Patent
LigandPNGBDBM293282(US10106504, Example 19)
Affinity DataEC50: <100nMpH: 7.55Assay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2019
Entry Details
Go to US Patent

Displayed 1 to 50 (of 1997 total ) | Next | Last >>
Jump to: